Eisai Expands Marketing and Supply Agreement for Antiobesity Age

Eisai Expands Marketing and Supply Agreement for Antiobesity Agent Lorcaserin to
Include Most Countries Worldwide 
Aims to Establish Weight Management Global Standard That Includes Drug Therapy 
Tokyo, Nov 8, 2013 - (JCN Newswire) -  Eisai Co., Ltd. announced today that it
has expanded the marketing and supply agreement it concluded with Arena
Pharmaceuticals, Inc. (Headquarters: California, United States; President &
CEO: Jack Lief, "Arena") in July 2010 for the antiobesity agent
lorcaserin hydrochloride (U.S. brand name: BELVIQ; "lorcaserin").
While the previous agreement granted Eisai exclusive rights to market and
distribute lorcaserin in 21 countries throughout the Americas, the expanded
agreement now includes most countries and territories worldwide, most notably
the European Union, Japan and China (and excluding South Korea, Taiwan,
Australia, New Zealand, Israel). 
Under this agreement, Eisai will be working in collaboration with Arena to
develop and seek approval of lorcaserin as an antiobesity treatment in multiple
eligible countries and territories worldwide. In addition to pursuing
regulatory approval for weight management in the expanded territories, Eisai
and Arena plan to investigate the potential of lorcaserin in new areas, such as
smoking cessation, a once-daily formulation, a fixed-dose combination with
phentermine, as well as explore lorcaserin's impact on diabetes and
cardiovascular outcomes. Eisai's commercialization rights are subject to
applicable regulatory approval.
BELVIQ is approved in the United States by the U.S. Food and Drug
Administration (FDA) as an adjunct to a reduced-calorie diet and increased
physical activity for chronic weight management in adult patients with an
initial body mass index (BMI) of 30 kg/m2 or greater, or 27 kg/m2 or greater in
the presence of at least one weight-related co-morbid condition. The drug has
been marketed in the U.S. by Eisai's U.S. subsidiary, Eisai Inc. Marketing
authorization has also been applied for in Mexico and Canada. 
In recent years, obesity has become a major global health problem, with more
than 1.4 billion adults worldwide believed to be overweight and approximately
500 million of that number qualifying as obese. Following the expansion of this
license agreement, the Eisai Group seeks to provide a new treatment option for
obesity in each country and territory while seeking to establish a weight
management global standard that includes drug therapy so as to further
contribute to increasing the benefits provided to patients and their families. 
Notes: 
1. About BELVIQ (lorcaserin hydrochloride) 
Discovered and developed by Arena Pharmaceuticals, Inc., BELVIQ is a new
chemical entity that is believed to decrease food consumption and promote
satiety by selectively activating serotonin 2C receptors in the brain. 
Activation of these receptors may help a person eat less and feel full after
eating smaller amounts of food. BELVIQ is approved by the U.S. Food and Drug
Administration (FDA) as an adjunct to a reduced-calorie diet and increased
physical activity for chronic weight management in adult patients with an
initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or
greater (overweight) in the presence of at least one weight-related co-morbid
condition. 
The use of BELVIQ in combination with other products for weight loss and its
effectiveness on cardiovascular morbidity and mortality have not been
established. BELVIQ was launched in the United States in June 2013 after
receiving a final scheduling designation from the U.S. Drug Enforcement
Administration (DEA). For further information on BELVIQ, including important
safety information (ISI), please visit the BELVIQ product website
(http://www.belviq.com). 
2. About Worldwide Overweight and Obesity 
In recent years, obesity has become a major global health problem, with more
than 1.4 billion adults worldwide believed to be overweight and approximately
500 million of that number qualifying as obese. By region, around 170 million
people in the United States and 150 million people in Europe are reported to
fall into one or both categories, while in Asia, the overweight and obese
population includes an estimated 100 million people in China and a further 25
million people in Japan. 
About Eisai 
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com. 
Contact: 
Investor Relations
Eisai Co., Ltd.
+81-3-3817-5327 
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net 
Provider ID: 00027976